Completed OBSERVATIONAL NCT01200550

The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients

An Epidemiological, Observational Study to Describe Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease (GERD)

Sponsor: AstraZeneca

Conditions Gastroesophageal Reflux Disease

Updated 7 times since 2017 Last updated: Apr 16, 2012 Started: Sep 30, 2010 Primary completion: Sep 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Gastroesophageal Reflux Disease, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Banja Luka, Bosnia and Herzegovina , Bijeljina, Bosnia and Herzegovina , Derventa, Bosnia and Herzegovina , Doboj, Bosnia and Herzegovina , Gradačac, Bosnia and Herzegovina , Gradiška, Bosnia and Herzegovina , Gračanica, Bosnia and Herzegovina , Hadžići, Bosnia and Herzegovina , Jelah, Bosnia and Herzegovina , Laktaši, Bosnia and Herzegovina and 13 more locations